Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine
暂无分享,去创建一个
V. Treska | P. Bachleda | P. Navrátil | A. Korn | M. Lao | H. Prestele | I. Matl | R. Michalský | M. Matthisson
[1] R. Lechler,et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. , 2001, Transplantation.
[2] O. Pankewycz,et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. , 2001, Transplantation proceedings.
[3] A. Monaco,et al. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. , 2001, Transplantation proceedings.
[4] H. E. Hansen,et al. The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.
[5] M. Hall,et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. , 1999, Transplantation.
[6] J. Kovarik,et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. , 1997, Transplantation.
[7] J. Soulillou,et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.
[8] J. Kovarik,et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. , 1996, Transplantation proceedings.
[9] D. Hernández-Gallardo,et al. Successful transplantation of a liver graft with a calcified hydatid cyst after back-table resection. , 1995, Transplantation.
[10] M. Schreier,et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. , 1995, Transplantation.